Nkarta (NKTX) Cash from Investing Activities (2019 - 2026)
Nkarta (NKTX) posted quarterly Cash from Investing Activities of $15.9 million for Q1 2026, down 70.71% year-over-year from $54.3 million in Q1 2025, and up 1342.88% quarter-over-quarter from $1.1 million in Q4 2025.
Nkarta (NKTX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Nkarta's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $15.9 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 70.71% year-over-year to $15.9 million; the TTM figure through Mar 2026 stood at $61.9 million (up 164.01% YoY), while the FY2025 annual figure was $100.3 million, up 177.43% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $15.9 million, up from $1.1 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $54.3 million in Q1 2025, with the low at -$109.3 million in Q2 2022.
- The 5-year median for Cash from Investing Activities is $4.7 million (2022), against an average of -$7.0 million.
- The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities jumped 3699.32% in 2023, then tumbled 3294.04% in 2024.
- Nkarta's Cash from Investing Activities stood at $4.7 million in 2022, then surged by 233.62% to $15.8 million in 2023, then sank by 128.54% to -$4.5 million in 2024, then surged by 124.4% to $1.1 million in 2025, then jumped by 1342.88% to $15.9 million in 2026.
- Business Quant data shows NKTX's Cash from Investing Activities at $15.9 million in Q1 2026, $1.1 million in Q4 2025, and $25.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.15 Mn |
| Jun 30, 2026 | 21.15 Mn |
| Mar 31, 2026 | 15.92 Mn |
| Mar 31, 2026 | 15.92 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Dec 31, 2025 | 1.10 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Sep 30, 2025 | 25.39 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Jun 30, 2025 | 19.49 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Mar 31, 2025 | 54.34 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Dec 31, 2024 | -4.52 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Sep 30, 2024 | -38.90 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Jun 30, 2024 | -107.63 Mn |
| Mar 31, 2024 | 21.49 Mn |
| Mar 31, 2024 | 21.49 Mn |